Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Untreated Mantle Cell Lymphoma
NCT04783415Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1), umbralisib and ublituximab in mantle cell lymphoma (MCL), sponsored by City of Hope. Primary endpoint: Complete Response Rate at 24 weeks. Started Mar 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)umbralisibublituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04783415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04783415.